Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6578326 | 0.81 | — | — | |
| SCHEMBL6519888 | 0.81 | — | — | |
| SCHEMBL6850579 | 0.79 | — | — | |
| SCHEMBL7031804 | 0.75 | HTT (0.40) | HTTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL19413865 | 0.74 | RIPK1 (0.45) | HTTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL7036076 | 0.74 | HTT (0.39) | HTTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL7036071 | 0.74 | CNR1 (0.44) | HTTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL9476287 | 0.74 | CTH (0.40) | HTTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL11369765 | 0.73 | HTT (0.35) | HTTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL2994316 | 0.72 | FAAH (0.43) | HTTLMNAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165541-A1 | METHOD FOR THE PREPARATION OF W-AMINO- ALKANEAMIDES AND W-AMINO-ALKANETHIOAMIDES AS WELL AS INTERMEDIATES OF THIS METHOD | SANDOZ AG | 2012-06-28 | — | — | US | disclosed |
| US-20120165541-A1 | METHOD FOR THE PREPARATION OF W-AMINO- ALKANEAMIDES AND W-AMINO-ALKANETHIOAMIDES AS WELL AS INTERMEDIATES OF THIS METHOD | SANDOZ AG | 2012-06-28 | — | — | US | disclosed |
| WO-2011012319-A1 | METHOD FOR THE PREPARATION OF W-AMINO-ALKANEAMIDES AND W-AMINO-ALKANETHIOAMIDES AS WELL AS INTERMEDIATES OF THIS METHOD | SANDOZ AG (CH) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165541-A1 | METHOD FOR THE PREPARATION OF W-AMINO- ALKANEAMIDES AND W-AMINO-ALKANETHIOAMIDES AS WELL AS INTERMEDIATES OF THIS METHOD | ABHD6, AADAT, LYPLA2 | HTT 3017/4885LMNA 1938/4885MEN1 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.